Why Shares of Relypsa Inc Are in the Red Today

After $-0.95 actual EPS reported by Relypsa Inc for the previous quarter, Wall Street now forecasts -7.37% EPS growth.

Relypsa (NASDAQ:RLYP) traded down 18.3337% during midday trading on Thursday, reaching $13.1891. $55.0 is the highest target while $15 is the lowest.

Right now, these patients are generally treated with a low potassium diet, reductions in use of other drugs causing hyperkalemia or with an older potassium binder, Kayexalate, which can be effective but also causes high rates of severe constipation.

Analysts at Zacks have given a short term rating of hold on Relypsa, Inc.

Relypsa, Inc. (NASDAQ:RLYP): 5 analysts have set the short term price target of Relypsa, Inc. Looking ahead the the firm raised its full year earnings to a range of $3.08 to $3.12 per share, expecting a continued strong performance in North America, while analysts expect $3.07 per share. The analyst at Morgan Stanley is much more bearish, believing patiromer peak sales will fall below $200 million annually because of the drug’s modest efficacy, difficulties convincing doctors to change the way they treat hyperkalemia and reimbursement hurdles. They now own 35.59 million shares or 0.00% more from 35.58 million shares in 2015Q1. The New York-based fund Orbimed Advisors Llc revealed it had acquired a stake worth about 2.05% of the fund’s stock portfolio in Relypsa. The Illinois-based fund Jhl Capital Group Llc is also positive about the stock, possessing 7.40M shares or 2.04% of their equity exposure. The stock was sold at an average price of $24.84, for a total value of $124,200.00. The insider Berman Lance sold 710 shares worth $17,586. The Company has completed its two-part pivotal Phase III trial of its product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood.

Relypsa, Inc.is a biopharmaceutical firm focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company has a market cap of $629.91 million and a P/E ratio of 0. It now has negative earnings.

The drug is made by Relypsa Inc., of Redwood City, Calif. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing from the United States Food and Drug Administration, or FDA.

The drug is of interest to those with chronic kidney disease, including those with diabetes.